[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_column_text]
March 20, 2019
VANCOUVER, British Columbia — Derm-Biome Pharmaceuticals Inc, a Vancouver based start-up biopharmaceutical company, will be reaching out to the world’s top veterinary researchers and veterinary schools for collaborative opportunities to show efficacy of its lead compound NVX-207, in the underserved area of cancers in canines, felines, and equines. Approximately 25% of companion animals will develop cancer in their lifetime, with some types of cancer being fatal if not treated. The pet cancer therapeutic market is expected to reach $300 million by 2025.
NVX-207 is a Betulinic Acid derivative that shows significant potential as a treatment for skin disease and skin cancer. In a Phase 1/2 canine study NVX-207 produced excellent tolerability as well as high clinical efficacy (tumor shrinkage in the absence of inflammation). In a Phase 1/2 study of two adult horses with equine melanoma, NVX-207 induced apoptosis while being well tolerated, leaving the researchers “optimistic that this could be a new cure for skin cancer in horses”. Most testing was done through intralesional applications, but a topical formulation also produced clear tumor regression.
For collaboration and investor inquiries: geberwein@derm-biome.com
Derm-biomepharmaceuticals.com
[/vc_column_text][vc_empty_space][vc_separator type=”normal” color=”#cccccc” thickness=”1″ up=”50″ down=”50″][/vc_column][/vc_row]